Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. The company has talked about capitalization of around INR70 crores planned for network expansion in FY27, but no mention of the source of this capex funding. Financials reflect expenses relating to expansion and new centers, impacting margins, but no reference to raising capital externally. Management focuses on organic growth, operational improvements, and internal accruals from the business. No question or answer during the call discussed plans for issuing new debt or equity

Any current/future capex/capital investment/strategic investment?

Planned capex for FY27 is around INR 70 crores. Capex includes opening five new hub centers and eight asset-light spoke centers. Expansion targets West Bengal, Bihar, Jharkhand, and Tripura. Two centers planned for last year had delayed openings; capex for those is nearly incurred. The company is focused on building specialized hubs and scaling diagnostics like genomics and advanced imaging. Long-term strategy includes sweating central reference infrastructure and improving throughput in new centers. Capex supports multi-state expansion, moving Suraksha from state leader to regional player.

Future growth expectations in sales/revenue/volumes?

FY26 revenue grew 23.1% YoY to INR3,104.1 million, with a three-year CAGR of 17.78% indicating strong structural growth. FY27 revenue growth guidance is around 15%, with management open to over-delivering but committing to a conservative 15%. Growth drivers include: - Expansion: Adding multiple new hubs and spoke centers targeting West Bengal, Bihar, Jharkhand, and Tripura, increasing network size from 68 centers in FY26 to 82+ in FY27. - New centers expected to contribute majority of growth; mature centers to contribute ~9% growth. - Focus on ramping up throughput and capacity utilizati

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth guidance for FY27 and beyond is around 15%, despite a 23% growth in FY26, with the company preferring cautious estimates and aiming to potentially over-deliver. EBITDA margin expected to stabilize at approximately 33% in FY27 due to expansion and pre-operative expenses, improving to around 35% in the mid-term and 38-39% over the long term as new centers mature. Mature centers deliver EBITDA margins of 36-37%, and new centers currently operate at negative EBITDA but are expected to breakeven within 5-12 months at the center level and 1-2 quarters later at the HO expense level

IN US

Sale is live|00:00:00left today

Suraksha Diagnostic LtdQ1 FY26Healthcare Services

Suraksha Diagnostic Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹273P/E: 47.8Market Cap: ₹1.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→FY26 revenue grew 23.1% YoY to INR3,104.1 million, with a three-year CAGR of 17.78% indicating strong structural growth.
→FY27 revenue growth guidance is around 15%, with management open to over-delivering but committing to a conservative 15%.
→Growth drivers include:
→ - Expansion: Adding multiple new hubs and spoke centers targeting West Bengal, Bihar, Jharkhand, and Tripura, increasing network size from 68 centers in FY26 to 82+ in FY27.
→ - New centers expected to contribute majority of growth; mature centers to contribute ~9% growth.
→ - Focus on ramping up throughput and capacity utilization in recently launched centers.
→ - Increasing share of specialized diagnostics and premium test mix, including genomics and advanced radiology.
→ - Geographic expansion beyond West Bengal, including Assam, Guwahati, and Tripura.
→Long-term, EBITDA margins projected to stabilize around 35%, reflecting operational leverage from scale.

Margin guidance

Category 2

→Revenue growth guidance for FY27 and beyond is around 15%, despite a 23% growth in FY26, with the company preferring cautious estimates and aiming to potentially over-deliver.
→EBITDA margin expected to stabilize at approximately 33% in FY27 due to expansion and pre-operative expenses, improving to around 35% in the mid-term and 38-39% over the long term as new centers mature.
→Mature centers deliver EBITDA margins of 36-37%, and new centers currently operate at negative EBITDA but are expected to breakeven within 5-12 months at the center level and 1-2 quarters later at the HO expense level.
→PAT growth was modest at 1.4% in FY26, impacted by expansion costs and depreciation; improvement likely as operating leverage improves.
→Earnings per share (EPS) and profits expected to strengthen as new centers mature, revenues scale, and cost efficiencies improve.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
→The company has talked about capitalization of around INR70 crores planned for network expansion in FY27, but no mention of the source of this capex funding.
→Financials reflect expenses relating to expansion and new centers, impacting margins, but no reference to raising capital externally.
→Management focuses on organic growth, operational improvements, and internal accruals from the business.
→No question or answer during the call discussed plans for issuing new debt or equity instruments at this time.

Order book

The transcript and report do not explicitly mention details about the current or expected order book or pending orders for Suraksha Diagnostic Limited. However, from the discussion, the following can be inferred regarding expansion and business pipeline: - Suraksha plans to open multiple new centers: 14 new centers in FY27, targeting to reach 82 centers by FY27-end and aiming for 100 centers by FY28. - Planned capex for expansion is around INR 70 crores, including adding five hubs and eight asset-light spoke centers across West Bengal, Bihar, Jharkhand, and Tripura. - Ongoing geographic expansion includes establishing hubs in Assam (Guwahati), Tripura, Bihar, and Jharkhand. - The company is focusing on ramping up throughput and capacity utilization for recently launched centers. - They are investing to scale specialized diagnostic capabilities like genomics and advanced imaging. No direct mention of order book or pending orders is provided.

Capex plans

Yes

→Planned capex for FY27 is around INR 70 crores.
→Capex includes opening five new hub centers and eight asset-light spoke centers.
→Expansion targets West Bengal, Bihar, Jharkhand, and Tripura.
→Two centers planned for last year had delayed openings; capex for those is nearly incurred.
→The company is focused on building specialized hubs and scaling diagnostics like genomics and advanced imaging.
→Long-term strategy includes sweating central reference infrastructure and improving throughput in new centers.
→Capex supports multi-state expansion, moving Suraksha from state leader to regional player.

How does Suraksha Diagnostic Ltd rank vs peers in Healthcare Services?

Pro feature

1Suraksha Diagnostic Ltd

Rev 3Mar 2

See full Healthcare Services sector rankings

Want more stocks like Suraksha Diagnostic Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio